KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Invested Capital (2016 - 2025)

Historic Invested Capital for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $17.3 billion.

  • Vertex Pharmaceuticals' Invested Capital rose 996.06% to $17.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 billion, marking a year-over-year increase of 996.06%. This contributed to the annual value of $16.5 billion for FY2024, which is 821.62% down from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Invested Capital stood at $17.3 billion, which was up 996.06% from $17.2 billion recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Invested Capital registered a high of $18.5 billion during Q1 2024, and its lowest value of $9.0 billion during Q1 2021.
  • Over the past 5 years, Vertex Pharmaceuticals' median Invested Capital value was $14.8 billion (recorded in 2024), while the average stood at $14.2 billion.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Invested Capital skyrocketed by 3897.83% in 2021, and later plummeted by 1105.49% in 2025.
  • Vertex Pharmaceuticals' Invested Capital (Quarter) stood at $10.7 billion in 2021, then surged by 34.98% to $14.4 billion in 2022, then grew by 25.19% to $18.0 billion in 2023, then fell by 8.22% to $16.5 billion in 2024, then grew by 4.79% to $17.3 billion in 2025.
  • Its Invested Capital stands at $17.3 billion for Q3 2025, versus $17.2 billion for Q2 2025 and $16.5 billion for Q1 2025.